CMEO Snack 3

Forecasting a Bright and Clear Tomorrow for Psoriasis Treatment

Supported through an educational grant from Bristol Myers Squibb

April W. Armstrong, MD, MPH
Professor of Dermatology
Associate Dean for Clinical Research
Director of Clinical Research Support, Southern California Clinical and Translational Science Institute (SC CTSI)
Vice Chair, Director of Clinical Trials and Outcomes Research
Director, Psoriasis Program, Department of Dermatology
Keck School of Medicine, University of Southern California
Los Angeles, CA

Melinda Gooderham, MSc, MD, FRCPC
Medical Director
SKiN Centre for Dermatology
Assistant Professor
Department of Medicine, Queen's University
Consultant Physician
Peterborough Regional Health Centre
Ontario, Canada

Today's Activity Is Eligible for ABIM MOC Credit and as a CME for MIPS Improvement Activity

Complete your post-test and evaluation at the conclusion of the activity

ABIM CME MOC ACCREDITED

Be sure to fill in your **ABIM ID number** and **DOB** (MM/DD) on the evaluation so we can submit your credit to ABIM

CME for MIPS IMPROVEMENT ACTIVITY

Over the next 90 days, actively work to incorporate improvements in your clinical practice from this presentation

- Complete the follow-up survey from CME Outfitters in approximately 3 months
- CME Outfitters will send you confirmation of your participation to submit to CMS attesting to your completion of a CME for MIPS Improvement Activity

CME OUTFITTERS

CME OUTFITTERS

Learning Objective

Evaluate efficacy and safety data for emerging therapies for the treatment of moderate-to-severe psoriasis.

Top 5 Goals of PsO Therapy



- Score for each goal was graded from 0 (not important) to 4 (very important)
- All of the top 5 treatment goals were considered to be important/very important by > 75% of the overall study population
- Treatment goals remained consistent regardless of severity of disease

N = 1,200
Armstrong A, et al. American Academy of Dermatology (AAD); 2020.

TYK2 Inhibitors and PsO

- First generation JAKi target 2 or 3 different JAKs resulting in a broader effect, but may also present more side effects than newer generation selective TYK2 inhibitors that target just one JAK[1]
- As knowledge about PsO has evolved, the focus on JAK inhibition has shifted and seems to be moving toward TYK2[2]

1. Kvist-Hansen A, et al. *Dermatol Ther (Heidelb)*. 2020;10(1):29-42.; 2. Nogueira M, et al. *Drugs*. 2020;80(4):341-352.

POETYK PSO-1 and POETYK PSO-2: PASI-75 Results at Week 16 and 24



Armstrong A. et al. Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, compared with placebo and apremilast in moderate to severe plaque psoriasis: results from the phase 3 POETYK PSO-1 Study. AAD Virtual Meeting Experience (VMX); 2021.

POETYK PSO-1 and POETYK PSO-2: PASI-75 Response Maintained at Week 52

- Among patients who achieved PASI-75 response at Week 24 with deucravacitinib and continued treatment with deucravacitinib, PASI-75 response was maintained at 52-weeks in over 80% of patients



Armstrong A. et al. Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, compared with placebo and apremilast in moderate to severe plaque psoriasis: results from the phase 3 POETYK PSO-1 Study. AAD Virtual Meeting Experience (VMX); 2021.

POETYK PSO-1 and POETYK PSO-2: Dermatology Life Quality Index (DLQI 0/1) at Wk 16 & 24



DLQI = Dermatology Life Quality Index

Armstrong A. et al. Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, compared with placebo and apremilast in moderate to severe plaque psoriasis: results from the phase 3 POETYK PSO-1 Study. AAD Virtual Meeting Experience (VMX); 2021.

Adverse Events

Adverse Events Weeks 0-16	• Adverse events were similar across each arm • 55.7% with deucravacitinib, 57.6% with apremilast, 49.6% with PBO • Discontinuation rates: 2.4% with deucravacitinib, 57.6% with apremilast, 49.6% with PBO
Serious Adverse Events	• Serious adverse events: 1.8% with deucravacitinib, 1.2% with apremilast, 2.9% with PBO • Discontinuation: 2.4% with deucravacitinib, 5.2% with apremilast, 3.8% in PBO • Exposure-adjusted incidence rate for herpes zoster: 0.9 per 100 patient years with deucravacitinib
Most Common Adverse Events	• Nasopharyngitis, upper respiratory tract infection, headache, diarrhea, and nausea • One death occurred in each treatment group deemed not to be related to study drugs

PBO = placebo

Armstrong A. et al. Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, compared with placebo and apremilast in moderate to severe plaque psoriasis: results from the phase 3 POETYK PSO-1 Study. AAD Virtual Meeting Experience (VMX); 2021.

Phase 3 BE SURE: Bimekizumab vs Adalimumab in PsO

Independent Achievement of DLQI 0/1, PASI Thresholds, or BSA Thresholds (OC)

	Week 24			Week 56	
	Bimekizumab Q4W	Bimekizumab Q4W/Q8W	Adalimumab	Bimekizumab Q4W	Bimekizumab Q4W/Q8W
DLQI 0/1	71.1% (106/149)	73.5% (108/147)	52.4% (76/145)	83.6% (117/140)	89.4% (127/142)
PASI = 0	71.8% (107/149)	71.1% (106/149)	32% (47/147)	81.4% (114/140)	79% (113/143)
PASI ≤ 2	91.3% (136/149)	94% (140/149)	59.9% (88/147)	96.4% (135/140)	94.4% (135/143)

OC = observed case; PASI = psoriasis area and severity index; Q4W = every 4 weeks

Blauvelt A. et al. AAD Virtual Meeting Experience (VMX); 2021. Poster ID: 27464.

Phase 3b BE RADIANT: Bimekizumab vs Secukinumab in Plaque PsO

Intention-to-Treat Population



Maintenance



CI = confidence interval; mg = milligram; N = number of patients; wk = week;
Reich K, et al. *N Engl J Med.* 2021 Apr 23. [Epub ahead of print].

Adverse Events

	Weeks 0 - 48		Weeks 16 - 48	
	Bimekizumab (N = 373)	Secukinumab (N = 370)	Bimekizumab every 4 wk (N = 147)	Secukinumab every 8 wk (N = 215)
Any AE	86.1%	81.4%	81%	75.3%
Serious AE	5.9%	5.7%	2.7%	4.2%
TEAE Discontinuation	3.5%	2.7%	2%	.5%
Severe AE	7%	4.1%	3.4%	5.1%
Death	1 (.3%)	1 (.3%)	0	1 (.3%)
Most common AE				
Upper respiratory tract infection	38.9%	41.6%	23.8%	28.8%
Oral candidiasis	19.3%	3.%	12.9%	16.7%
Urinary tract infection	6.7%	5.9%	7.5%	4.7%

AE = adverse event; TEAE = treatment emergent adverse event

Reich K, et al. *N Engl J Med.* 2021 Apr 23. [Epub ahead of print].

SMART Goals

Specific, Measurable, Attainable, Relevant, Timely

- Engage patients in discussions about their goals for treatment of their PsO
- Agents in development offer new mechanisms of action (TYK2) and monoclonal antibodies that offer improvements in skin clearance and quality of life

CME Outfitters Snack 1

Why New Treatments are Needed for the Management of Psoriasis

CME Outfitters Snack 2

Refining Treatment Targets for the Management of Psoriasis

www.CMEOutfitters.com/dermatology-hub